Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)
Product News Jan 06, 2019
Dr. Brian Ogilvie, Vice President of Scientific Consulting for Sekisui XenoTech
Sekisui XenoTech has created a Scientific Advisory Board (SAB) of renowned scientists and thought leaders in the pharmaceutical industry.
Initially this board will be made up of four experts specializing in Absorption, Distribution, Metabolism and Excretion (ADME) studies, as well as Drug Metabolism and Pharmacokinetics (DMPK). The board will be led by Dr. Brian Ogilvie, Vice President of Scientific Consulting for Sekisui XenoTech.
Dr. Ogilvie sought out thought leaders that have distinctive perspectives on the pharmaceutical industry that have been formulated from their independent expertise and numerous years of experience. Through their insight Sekisui XenoTech will be guided to better serve the industry by anticipating growth trends, scientific innovation and ultimately the greater needs of its customers.
The SAB consists of: Dr. Griff Humphreys, Principal with Aranmore Pharma Consulting; Dr. Jane Kenny, Associate Director/Principal Scientist at Genentech; Dr. Ajay Madan, Vice President, Development for Crinetics Pharmaceuticals; and Dr. Larry Wienkers, Owner of Wienkers Consulting, LLC. For more information on the SAB members, please consult Sekisui XenoTech’s website.
“I am excited to bring this group together. The combination of our internal knowledge and 25 years of experience in the industry with the infusion of the extensive expertise and well-respected knowledge brought by this SAB will serve to set Sekisui XenoTech apart as the leader in in vitro ADME/DMPK/DDI testing services and products.” stated Dr. Ogilvie.